Lung AI vs InVision Precision Cardiac Amyloid

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

InVision Precision Cardiac Amyloid

by InVision Medical Technology Corporation

AI Verdict

These tools are adjacent rather than direct competitors, as they both leverage AI in cardiology but serve different functions and workflows. Tool A, "Lung AI," is a handheld ultrasound device with integrated AI for real-time cardiac and lung scanning, offering broad diagnostic support. In contrast, Tool B, "InVision Precision Cardiac Amyloid," is specialized software designed to analyze existing echocardiogram studies specifically for the detection of cardiac amyloidosis.

Choose Lung AI if…

Choose Lung AI if you require a portable, real-time point-of-care ultrasound solution for immediate diagnostic insights, particularly in emergency medicine or critical care settings. Its on-device AI capabilities for lung conditions like pleural effusion and consolidation, alongside general cardiac assessments, make it ideal for rapid bedside evaluations and guided image capture.

View Lung AI →

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your cardiology department needs specialized AI-powered software to enhance the detection and diagnosis of cardiac amyloidosis from existing echocardiogram studies. This tool is best suited for integrating into established clinical workflows to provide precise, evidence-based analysis for a specific, complex condition, aiming for earlier intervention and improved patient outcomes.

View InVision Precision Cardiac Amyloid →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung AI	InVision Precision Cardiac Amyloid
Pricing	Unknown	Subscription
Deployment	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.	Software as a Medical Device (SaMD), integrated into clinical workflows for echocardiography labs.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A emphasizes an 'easy-to-use' handheld ultrasound platform with 'guided image capture' and 'AI-powered POCUS education and training' (Exo U). This focus on intuitive design, portability, and integrated learning resources suggests a superior user experience, especially for point-of-care applications. Tool B integrates into existing workflows, which is good, but Tool A's comprehensive approach to usability with new hardware gives it an edge.

Clinical Value

InVision Precision Cardiac Amyloid

While Tool A offers real-time AI for common lung and cardiac conditions, Tool B focuses on the detection of cardiac amyloidosis, a life-threatening and often underdiagnosed disease. Its AI algorithm is 'evidence-based' and 'peer-reviewed and published in JAMA Cardiology,' indicating a high level of clinical rigor and impact for a challenging diagnosis. This specific, high-impact clinical problem with strong validation gives Tool B a slight advantage in terms of specialized clinical value.

Pricing & Value

InVision Precision Cardiac Amyloid

Tool B provides transparent starting pricing at '$49/mo' and indicates options for enterprise and volume discounts, offering a clear understanding of potential costs. In contrast, Tool A only states 'contact for pricing' with no details available. The transparency of Tool B's pricing model allows for a more direct assessment of its value proposition.

Enterprise Readiness

InVision Precision Cardiac Amyloid

Both tools are FDA cleared and HIPAA compliant. However, Tool B is deployed as 'Software as a Medical Device (SaMD), integrated into clinical workflows for echocardiography labs' and explicitly mentions 'enterprise pricing and volume discounts.' This indicates a clear strategy for seamless integration into existing hospital IT infrastructure and procurement processes, making it slightly more enterprise-ready from a software deployment perspective.

Innovation

Lung AI

Tool A is pioneering a 'high-performance, handheld ultrasound platform that uses artificial intelligence' with 'on-device AI processing' that 'operates without internet.' This integration of advanced AI directly into a portable hardware device for real-time, multi-application use represents a significant innovation in the medical imaging and point-of-care space. While Tool B offers an innovative AI algorithm for a specific diagnosis, Tool A's combination of hardware and software for broad, real-time application is more fundamentally disruptive.

Support & Docs

Lung AI

Tool A explicitly lists 'Exo U (AI-powered POCUS education and training)' as a key feature, demonstrating a commitment to user enablement and ongoing education for its platform. Tool B does not provide any information regarding support or documentation in the given facts. Therefore, based on the available data, Tool A shows a clear advantage in providing resources for user support and understanding.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung AI	InVision Precision Cardiac Amyloid
Name	Lung AI	InVision Precision Cardiac Amyloid
Company	Exo	InVision Medical Technology Corporation
Tagline	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.	Improving the precision and accuracy of cardiovascular imaging.
Primary AI Detections	AI-powered detection of pleural effusion, consolidation/atelectasis, and automated AI-based indicators for cardiac conditions.	AI-powered detection of cardiac amyloidosis, evaluation of transthoracic echocardiogram studies.
Supported Specialties	Cardiology, Emergency Medicine, Pulmonology	Cardiology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Lung AI and InVision Precision Cardiac Amyloid.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows, considering one is a real-time POCUS device and the other is software for post-acquisition echo analysis?

Lung AI is integrated directly into the Exo Iris handheld ultrasound device, providing real-time AI insights at the point of care for immediate decision-making. InVision Precision Cardiac Amyloid is a Software as a Medical Device (SaMD) designed to integrate into existing echocardiography lab workflows for post-acquisition analysis of transthoracic echocardiogram studies, often installed as a third-party application to an institution's PACS system.

For which specific clinical scenarios or patient populations are these tools best suited, given their distinct AI capabilities?

Lung AI is ideal for point-of-care assessments in emergency medicine, pulmonology, and cardiology, assisting with real-time detection of conditions like pleural effusion, consolidation/atelectasis, and automated cardiac indicators. InVision Precision Cardiac Amyloid is specifically designed for cardiologists and radiologists to aid in the earlier detection and diagnosis of cardiac amyloidosis in patients with heart failure symptoms, supporting both AL and ATTR Cardiac Amyloidosis.

What evidence supports the accuracy and sensitivity of each tool's AI algorithms, particularly for critical diagnoses?

InVision Precision Cardiac Amyloid's AI algorithm for cardiac amyloidosis detection is evidence-based, peer-reviewed, and published in JAMA Cardiology, with further validation showing no racial bias and international confirmation of model performance. Lung AI has demonstrated high accuracy in detecting pleural effusion and consolidation/atelectasis, with studies showing improved clinician sensitivity and specificity when assisted by the AI, and its AI applications are trained on over 100,000 POCUS images from real-world settings.

What resources or features are available to help clinicians quickly learn and effectively utilize each tool in their practice?

Lung AI offers guided image capture for optimal scans and includes Exo U, an AI-powered POCUS education and training platform with short, in-app how-to videos, to support users in learning correct image acquisition and interpretation. InVision Precision Cardiac Amyloid integrates into existing echocardiography workflows, and while specific training resources aren't detailed, its design aims to streamline interpretation and standardize measurements within the echo lab.

How do these tools support multi-site rollouts, especially concerning data transfer, security, and consistent performance across different clinical environments?

Lung AI processes AI on-device, allowing it to operate without an internet connection, which can simplify multi-site deployment and enhance data security by keeping patient data local. InVision Precision Cardiac Amyloid is a Software as a Medical Device (SaMD) integrated into clinical workflows, suggesting its deployment would involve standard software integration processes within each site's existing IT infrastructure.

What is the expected time-to-value for a new practice implementing either tool, and are customer references available to demonstrate real-world impact?

Lung AI aims for rapid time-to-value by enabling real-time, critical decisions at the point of care with its easy-to-use handheld platform, accelerating diagnosis and patient care pathways. InVision Precision Cardiac Amyloid focuses on earlier detection of cardiac amyloidosis to improve patient outcomes, and its integration into existing workflows is designed to streamline interpretation and surface undiagnosed disease.

Do these tools offer audit-trail features to track AI-assisted diagnoses, user interactions, or changes made based on the AI's output?

The provided information does not explicitly detail audit-trail features for either Lung AI or InVision Precision Cardiac Amyloid. Physicians would need to inquire directly with the companies regarding the availability and specifics of such functionalities for tracking AI-assisted diagnoses and user interactions.